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T he morbidity due to tachycardia seems to be rela-tively higher in critically ill patients than in other 
patients,  but the relationship between tachycardia and 
mortality has not been well studied.  In contrast,  the 
association between arrhythmia (mostly consisting of 
atrial fibrillation [Af]) and postoperative [1],  critically 
ill [2-4],  and septic patients [5-15] has been investi-
gated in many studies.  Tachycardia is commonly seen in 
intensive care unit (ICU) settings,  e.g.,  intensive surgi-
cal,  neurological,  and medical settings.  There have 
been few investigations regarding whether a higher 
heart rate (HR) or a prolonged higher HR actually 
affects patient outcomes.  We conducted the present 
study to evaluate the association between tachycardia 
and mortality in critically ill patients.  The association 
between tachycardia and mortality was investigated in 
critically ill patients in a University Hospital ICU 
(Okayama University Hospital,  Okayama,  Japan).  Our 
hypothesis was that higher HR and prolonged tachycar-
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Tachycardia is common in intensive care units (ICUs).  It is unknown whether tachycardia or prolonged tachy-
cardia affects patient outcomes.  We investigated the association between tachycardia and mortality in critically 
ill patients.  This retrospective cohort study’s primary outcome was patient mortality in the ICU and the hospi-
tal.  We stratified the patients (n = 476) by heart rate (HR) as LowHR,  MediumHR,  and HighHR groups.  We 
also stratified them by their durations of HR > 100 (prolonged HR; tachycardia): MildT,  ModerateT,  and 
SevereT groups.  We determined the six groups’ mortality.  The ICU mortality rates of the LowHR,  MediumHR,  
and HighHR groups were 1.0%,  1.5%,  and 7.9%,  respectively; significantly higher in the HighHR vs. LowHR 
group.  The in-hospital mortality rates of these groups were 1%,  4.5%,  and 14.6%,  respectively; significantly 
higher in the HighHR vs. LowHR group.  The ICU mortality rates of the MildT,  ModerateT,  and SevereT 
groups were 0.9%,  5.6%,  and 57.1%,  respectively.  The mortality of the HRT = 0 (i.e.,  all HR ≤ 100) patients was 
0%.  The in-hospital mortality rates of the MildT,  ModerateT,  and SevereT groups were 1.8%,  16.7%,  and 
85.7%,  respectively; that of the HRT = 0 patients was 0.5%.  Both higher HR and prolonged tachycardia were 
associated with poor outcomes.
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dia cause worse patient outcomes.
Patients and Methods
Study design. This study was approved by the 
Institutional Review Board (IRB) of Okayama University 
Hospital.  The requirement of written informed consent 
was waived by the IRB due to the retrospective cohort 
design of the study.  This manuscript adheres to the 
applicable STROBE guidelines.  The primary outcome 
was patient mortality in the ICU and in the hospital.  
After the IRB’s approval was obtained,  we reviewed the 
records of patients in the ICU and in the hospital from 
September 1,  2014 to August 31,  2015,  and the patients’ 
HR values were extracted from automatically recorded 
vital signs.
A total of 1,863 patients were admitted to Okayama 
University Hospital’s ICU during this period of time.  Of 
these patients,  we excluded the cases of the patients 
who were admitted to the ICU more than twice,  or 
were discharged from the ICU within 48 h of their 
admission to the ICU,  or were under 17 years old 
(Fig. 1).  The remaining 476 patients were eligible and 
enrolled.
We first stratified the patients into three groups 
based only on their HR values: LowHR (100 ≤ HR 
< 110),  MediumHR (110 ≤ HR < 120) and HighHR (HR 
≥ 120).  All patients’ HR values were recorded automat-
ically in the ICU every 60 sec.  For this stratification,  
when we describe a patient as having had an HR value 
≥ 100,  the HR was > 100 continuously for > 10 min in 
that patient.  When HR values that were in-between 
each group’s thresholds were observed for > 10 min,  the 
enrolled group was determined.  For example,  when a 
patient’s HR values were 105,  106,  108,  etc.  for 
> 10 min,  the patient was assigned to the 100 ≤ HR 
< 110 (LowHR) group.
We then created another three patient groups based 
on the duration of higher HR (tachycardia),  according 
to our hypothesis that a prolonged higher HR is more 
life-threatening.  The duration of higher HR was mea-
sured using the patients’ HR records,  and when the HR 
value was over 100,  it would have been counted as 
(HR-100).  The concept of prolonged tachycardia is 
expressed by the following formula: (HR-100) × the 
time duration (min) during which the HR was > 100.  
Since the result of this calculation is HR × time,  we 
named this value the “HRT.” As a result,  we created the 
formula HRT = (HR-100) × the time duration (min) 
during which the patient’s HR was > 100.  This expresses 
a variable equal to the areas under the curve (AUC) 
over 100 beats per min.
Using this formula and the patients’ data,  we strati-
fied the 476 patients into the MildT (1 ≤ HRT < 50400),  
ModerateT (50400 ≤ HRT < 151200),  and SevereT 
(HRT ≥ 151200) tachycardia groups.  The label ‘1 ≤ HRT 
< 50400’ indicates that the HR value 105 was recorded 
in the patient for 1 week: (105-100) × 60 × 24 × 7.
The statistical analyses were performed with JMP 
Pro® ver. 12.2.0 (Tokyo),  and differences were consid-
ered significant when the p-values were < 0.05.  The 
p-values for mortality were calculated with Fisher’s 
exact test.  The p-values for the Kaplan-Meier curves 
were calculated by log lank test.
Results
The mean age of all patients was 58.4 ± 0.9 years 
(Table 1).  Of the 476 patients,  200 (42%) were female.  
The severity of illness was validated with the acute 
physiology and chronic health evaluation II (APACHE 
II) score,  and the average score was 16.6 ± 0.3 (Table 1).  
β-blockers were administered to 117 (24.6%) patients,  
and sinus rhythm was preserved in 391 (82.1%) patients 
(Table 1).
The characteristics of the patients in the LowHR,  
MediumHR,  and HighHR groups (stratification by HR 
only) are summarized in Table 1.  The ICU mortality 
rates of the LowHR,  MediumHR,  and HighHR groups 
were 1.0%,  1.5%,  and 7.9%,  respectively; the mortal-
ity of the HR < 100 group was 0%.  The ICU mortality 
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Fig. 1 Exclusion criteria. Of the total of 1,863 patients,  476 patients 
were eligible and enrolled.
was significantly higher in the HighHR group compared 
to the LowHR group (Fig. 2A).  The in-hospital mortal-
ity rates of the LowHR,  MediumHR,  and HighHR 
groups were 1.0%,  4.5%,  and 14.6%,  respectively; that 
of the HR < 100 group was 0.5%.  In-hospital mortality 
was significantly higher in the HighHR group compared 
to the LowHR group (Fig. 2A , B).
The odds ratios (ORs) of MediumHR and HighHR 
against LowHR were calculated.  In terms of ICU mor-
tality,  the ORs of MediumHR and HighHR were 1.5 
(95%CI: 0.1-37.2) and 7.3 (95%CI: 1.2-138.0,  p< 0.05),  
respectively.  With respect to in-hospital mortality,  the 
ORs of MediumHR and HighHR were 4.5 (95%CI:  
0.6-91.7) and 13.7 (95%CI: 2.5-256.6,  p < 0.01),  
respectively (Table 2).
We next analyzed the three groups stratified by the 
duration of HR > 100: MildT,  ModerateT,  and SevereT.  
The groups’ patient characteristics are shown in Table 3.  
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Table 1 Stratiﬁcation of patients by HR
Total LowHR MediumHR HighHR
Variables (n＝476)
HR＜100
(n＝222)
100≦HR＜1110
(n＝98)
110≦HR＜120
(n＝67)
120≦HR
(n＝89)
Age 58.4±0.9 59.8±1.2 60.9±1.9 55.4±2.3 54.6±2.0
The number
of Female (%)
200
(42)
92
(41.4)
53
(54.1)
23
(34.3)†
32
(36.0)†
APACHEⅡ
Score 16.6±0.3 15.7±0.4 16.3±0.7 16.9±0.8 18.8±0.7
Use of
β-blockers (%)
117
(24.6)
45
(20.3)
23
(23.5)
17
(25.4)
41
(46.1)＊
Sinus rhythm
(%)
391
(82.1)
195
(87.8)
81
(82.7)
55
(82.1)
60
(67.4)†
Int. Med. (%) 38 (8.0) 13 (5.9) 4 (4.1) 4 (10.5) 17 (14.4)
GI Surg. 138 (29.0) 61 (27.5) 30 (30.6) 10 (26.3) 37 (31.4)
Lung Surg. 26 (5.5) 6 (2.7) 4 (4.1) 4 (10.5) 12 (10.2)
Esop h. Surg. 13 (2.7) 7 (3.2) 2 (2.0) 2 (5.3) 2 (1.7)
Cardiac surg. 54 (11.3) 23 (10.4) 18 (18.4) 2 (5.3) 11 (9.3)
Neuro Surg. 40 (8.4) 24 (10.8) 7 (7.1) 1 (2.6) 8 (6.8)
Others 167 (35.1) 88 (39.6) 33 (33.7) 15 (39.5) 31 (26.3)
（†: ＜0.05,  ＊: ＜0.01）
LowHR
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Fig. 2 A,  The mortality in the ICU and in the hospital.  The patients were stratiﬁed by HR alone as LowHR (100 ≤HR ＜110),  
MediumHR (110 ≤HR ＜120),  and HighHR (HR ≥120).  Both the ICU and in-hospital mortality rates were signiﬁcantly higher in the 
HighHR group compared to the LowHR group.  †p＜0.05,  ＊p＜0.01 by Fisherʼs exact test; B,  The Kaplan-Meier curves of the LowHR,  
MediumHR,  and HighHR groups.  These results conﬁrmed those illustrated in panel A.  †p＜0.05,  ＊p＜0.01 by log rank test.
The usage of β-blockers was significantly higher in the 
ModerateT and SevereT groups compared to the MildT 
group.  For the MildT,  ModerateT,  and SevereT groups,  
the ICU mortality rates were 0.9%,  5.6%,  and 57.1%,  
respectively,  while that of the HRT = 0 group was 0%,  
since HR ≤ 100 means HRT = 0.  The ICU mortality was 
significantly higher in the SevereT group than in the 
MildT group (p < 0.01) (Fig. 2A).  The in-hospital mor-
tality rates of the MildT,  ModerateT,  and SevereT 
groups were 1.8%,  16.7%,  and 85.7%,  respectively;  
that of the HRT = 0 group was 0.5%.  In-hospital mor-
tality was significantly higher in the ModerateT and 
SevereT groups compared to the MildT group (p < 0.05 
and p < 0.01,  respectively) (Fig. 3A , B).
We calculated the ORs of ModerateT and SevereT 
against MildT.  In terms of ICU mortality,  the ORs of 
ModerateT and SevereT were 3.3 (95%CI: 0.2-24.0) 
and 75.0 (95%CI: 12.9-514.9,  p < 0.01),  respectively.  
For in-hospital mortality,  the ORs of ModerateT and 
SevereT were 5.5 (95%CI: 1.1-21.5,  p < 0.05) and 165.8 
(95%CI: 24.6-3333.7,  p < 0.01),  respectively (Table 4).
Discussion
Our retrospective analyses revealed three major 
findings.  First,  higher HR was associated with poor 
patient outcomes and tachyarrhythmia.  Second,  pro-
longed tachycardia and higher HR were also profoundly 
associated with poor patient outcomes.  Finally,  
patients with HR < 100 had substantially lower mortal-
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Table 2 Odds Ratio of group MediumHR and HighHR to LowHR
Groups OR of mortality in ICU OR of mortality in hospital
OR 95%CI p value OR 95%CI p value
LowHR 1 - - 1 - -
MediumHR 1.5 0.1-37.2 0.79 4.5 0.6-91.7 0.16
HighHR 7.3 1.2-138.0 ＜0.05† 13.7 2.5-256.6 ＜0.01＊
（†: ＜0.05,  ＊: ＜0.01）
Table 3 Stratiﬁcation of patients by HRT
Total MildT ModerateT SevereT
Variables
(n＝476)
HR×duration
0
(n＝222)
HR×duration
1-50,400
(n＝229)
HR×Duration
50,400-151,200
(n＝18)
HR×Duration
151,200-
(n＝7)
Age 58.4±0.9 59.8±1.2 60.9±1.9 57.2±5.5 47.3±8.3
The number
of Female (%)
200
(42)
92
(41.4)
97
(42.4)
9
(50.0)
2
(28.6)
APACHEⅡ
Score 16.6±0.3 15.7±0.4 17.0±0.4 20.1±1.6 22.9±2.5
Use of 
β-blockers (%)
117
(24.6)
45
(20.3)
23
(23.5)
11
(61.1)＊
5
(71.4)†
Sinus rhythm
 (%)
391
(82.1)
195
(87.8)
81
(82.7)
11
(61.1)
5
(71.4)
Int. Med. (%) 38 (8.0) 13 (5.9) 4 (8.7) 4 (22.2) 1 (7.7)
GI Surg. 138 (29.0) 61 (27.5) 30 (29.3) 10 (33.3) 4 (30.8)
Lung Surg. 26 (5.5) 6 (2.7) 4 (6.6) 4 (22.2) 1 (7.7)
Esop h. Surg. 13 (2.7) 7 (3.2) 2 (2.6) 0 (0) 0 (0)
Cardiac surg. 54 (11.3) 23 (10.4) 18 (13.1) 1 (5.6) 0 (0)
Neuro Surg. 40 (8.4) 24 (10.8) 7 (7.0) 0 (0) 0 (0)
Others 167 (35.1) 88 (39.6) 33 (32.7) 3 (16.7) 7 (53.8)
（†: ＜0.05,  ＊: ＜0.01）
ity.
Regarding the first finding that higher HR alone 
contributed to poor patient outcomes,  our results sug-
gest that both the ICU mortality and the in-hospital 
mortality of patients with HR ≥ 120 (the HighHR group) 
were significantly higher than those of the patients with 
100 ≤ HR < 110 (the LowHR group) (Fig. 2A , B).  With 
this patient stratification,  the modality of arrhythmia,  
which is predominantly Af,  was significantly higher 
compared to the LowHR patients with HR < 100,  the 
LowHR group,  or the MediumHR group (Table 1).  
This suggests that higher HR has a significant associa-
tion not only with Af or other arrhythmias but also with 
significantly increased mortality.  Although the associa-
tion between arrhythmia and mortality was unclear in 
the present study,  there were no cardiac deaths,  such as 
those due to ventricular fibrillation.
Our second major finding was that prolonged tachy-
cardia with higher HR contributed to higher mortality 
of patients in the ICU and hospital.  Interestingly,  even 
though mortality was highest in the SevereT group,  the 
number of patients with arrhythmia in this group was 
not significantly higher than the other groups’.  This 
result suggests that prolonged tachycardia with higher 
HR contributes independently to increased mortality.
Finally,  the most surprising finding was that criti-
cally ill patients with HR <100 had 100% survival in the 
ICU,  and their hospital survival rate was still > 99%.  
Overall,  12.2% of the 222 patients with HR < 100 had 
arrhythmias,  which suggests that even if a patient has 
an arrhythmia,  maintaining his or her HR at < 100 may 
be beneficial.
To the best of our knowledge,  the association 
between tachycardia and mortality has been investi-
gated very rarely [16],  but the relationship between Af 
and mortality has been investigated several times [4-12 ,  
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Table 4 Odds Ratio of group SevereT and ModerateT to MildT
Group OR of mortality in ICU OR of mortality in hospital
OR 95%CI p value OR 95%CI p value
MildT 1 - - 1 - -
ModerateT 3.3 0.2-24.0 0.35 5.5 1.1-21.5 ＜0.05†
SevereT 75.0 12.9-514.9 ＜0.01＊ 165.8 24.6-3333.7 ＜0.01＊
（†: ＜0.05,  ＊: ＜0.01）
A
Mortality in the ICU
Mortality in the hospital
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
0 1-50400 50400-151200 151200-
MildT ModerateT SevereT
＊
＊
†
B
timeline (days)
MildT
ModerateT＊
SevereT＊
1.0
0.8
0.6
0.4
0.2
0 20 40 60 80 100 120 140
HRT1_50400
HRT50400_151200
HRT151200＜
Fig. 3 A,  The mortality in the ICU and in the hospital.  The patients were stratiﬁed by (HR-100)×duration of time (min) when HR is 
＞100: MildT (1 ≤HRT ＜50400),  ModerateT (50400 ≤HRT ＜151200),  and SevereT (HRT ≥151200).  In terms of both the ICU and 
in-hospital mortality,  the mortality rates of the SevereT group were signiﬁcantly higher than those of the MildT group.  †p＜0.05,  ＊p＜
0.01 by Fisherʼs exact test; B,  The Kaplan-Meier curve of the MildT,  ModerateT,  and SevereT groups.  The survival rates of ModerateT 
and SevereT groups were signiﬁcantly higher than those of the MildT group,  conﬁrming the results shown in panel A.  †p＜0.05,  ＊p＜
0.01 by log rank test.
15-17].  Several studies have shown an association 
between Af and sepsis or septic shock [5-9 , 11-17].  
Annane concluded that supraventricular arrhythmias 
did not significantly impact the hospital survival of crit-
ically ill patients [3],  while other researchers suggested 
that supraventricular arrhythmia,  especially new-onset 
Af,  had quite a large impact on the survival of patients 
with sepsis [5 , 7-9 , 11 , 12].  Our hospital’s ICU has a 
mixed-function design,  and it functions relatively more 
like a surgical ICU,  but the present HighHR group still 
had significantly more patients with arrhythmias and 
had higher mortality rates.  Theerwit noted that criti-
cally ill patients with HR > 130 had a higher mortality 
than patients with HR ≤ 130 [6]; our present findings 
might reflect that result.
Although there have been few reports of the associ-
ation between HR and patient outcomes,  a few research 
groups have investigated the effect of the β1-receptor 
blocker esmolol in patients with septic shock [13 , 15].  
They concluded that esmolol could achieve HR reduc-
tion to the target level without adverse events [15] and 
without changing cardiac output,  whereas norepineph-
rine requirements were reduced [13].  There is only one 
report of an investigation of the relationships of HR and 
prolonged tachycardia with patient outcomes [18],  and 
the report’s authors concluded that critically ill patients 
with high cardiac risk and HR values > 95 for ≥ 12 h in 
their ICU stay had a significant risk of major cardiac 
events [19].  Whether HR reduction would have had any 
survival benefit in critically ill patients remains 
unknown.  Further studies are needed to determine 
whether HR reduction contributes to better patient out-
comes.
Study limitations. This investigation had some 
limitations.  First,  since this was a single-center retro-
spective,  observational,  cohort study,  the results have 
limited generalizability.  Second,  the cohort consisted 
mainly of postoperative patients,  and the baseline char-
acteristics of each group were not similar.  This could 
have resulted in some confounding bias to the out-
comes.  Third,  regarding the stratification of the groups,  
each cut off-level of HR or HRT was arbitrary.  These 
cut-off levels were sensible but not statistically gener-
ated,  and the numbers of patients categorized to the 
ModerateT and SevereT groups were very low.  Fourth,  
the HRT might have been relatively shorter if critically 
ill patients died soon after being admitted to the ICU.
In conclusion,  the results of our analyses indicate 
that not only higher HR but also prolonged tachycardia 
are associated with poor patient outcomes.
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